Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.62 |
---|---|
High | 0.62 |
Low | 0.62 |
Bid | 0.56 |
Offer | 0.590 |
Previous close | 0.62 |
Average volume | 385.00 |
---|---|
Shares outstanding | 188.84m |
Free float | 188.00m |
P/E (TTM) | -- |
Market cap | 113.30m USD |
EPS (TTM) | -0.1096 USD |
Data delayed at least 15 minutes, as of Nov 21 2024 07:08 GMT.
More ▼
- Lineage Cell Therapeutics Announces First Closing of up to $66 Million Registered Direct Offering
- Lineage Cell Therapeutics Announces Pricing of up to $66 Million Registered Direct Offering
- Lineage Cell Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
- Lineage Cell Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024
- Lineage Cell Therapeutics to Present at the Maxim Group 2024 Virtual Healthcare Summit
- OpRegen® (RG6501) Phase 1/2a Results to Be Featured at International Society for Stem Cell Research (ISSCR) 2024 Copenhagen International Symposium
- Lineage Presents Preclinical Data on Its Auditory Neuronal Cell Transplant Program, ReSonance™, at the 59th Annual Inner Ear Biology Workshop
More ▼